Journal: Clinical, Cosmetic and Investigational Dermatology

Article Title: Emerging clinical applications of selected biomarkers in melanoma

doi: 10.2147/CCID.S49578

Figure Lengend Snippet: List of selected tissue biomarkers in melanoma

Article Snippet: BRAFV600E , Serine/threonine protein kinase , VE1 (Spring Bioscience) , 1:50 , C , None available , Detect the presence of BRAFV600E mutation.

Techniques: Concentration Assay, Control, Mutagenesis, Ubiquitin Proteomics

Journal: Diagnostics

Article Title: Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

doi: 10.3390/diagnostics12030751

Figure Lengend Snippet: Analysis of discordant results.

Article Snippet: Vallée et al. 2019 [ ] , Melanoma (metastatic and primary) , 65 , Clone VE1 (Eurobio) , BRAF V600E , No , NS , FFPE tissue , Idylla NRAS- BRAF -EGFR S492R Mutation Test , V600 E/E2/D V600 K/R , 89 (overall) , 82,3 , 100 , 100 , 93.

Techniques: Diagnostic Assay, Amplification

Journal: Diagnostics

Article Title: Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

doi: 10.3390/diagnostics12030751

Figure Lengend Snippet: Example of discordant results. ( a – d ), a micro-metastatic sentinel lymph node that expressed BRAF V600E when analyzed by IHC and was negative with the BRAF Idylla test despite delayed amplification. ( e – g ), a subcutaneous melanoma metastasis considered negative for IHC BRAF V600E when compared to the control. ( g ) (some background noise due to intracytoplasmic pigment), when stained with a red chromogen the interpretation remains equivocal ( h , i ) and positive with the Idylla method. ( a , e ) HES stain ×20; ( b ) Melan A IHC ×20 (Clone A103, Roche Ventana); ( c , f ) BRAF V600E IHC ×20 (Clone VE1, Roche Ventana); ( g ) BRAF V600E IHC ×40 external control showing viable tumor cells and melanophages; ( h ) BRAF V600E IHC ×20 (Clone VE1, Roche Ventana—Red detection kit); ( i ) BRAF V600E IHC ×40 external control viable tumor cells with red chromogen; ( d , j ) Amplification curves with the Idylla Explore tool.

Article Snippet: Vallée et al. 2019 [ ] , Melanoma (metastatic and primary) , 65 , Clone VE1 (Eurobio) , BRAF V600E , No , NS , FFPE tissue , Idylla NRAS- BRAF -EGFR S492R Mutation Test , V600 E/E2/D V600 K/R , 89 (overall) , 82,3 , 100 , 100 , 93.

Techniques: Amplification, Control, Staining

Journal: Diagnostics

Article Title: Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

doi: 10.3390/diagnostics12030751

Figure Lengend Snippet: Overview of studies combining immunohistochemistry and Idylla for BRAF evaluation.

Article Snippet: Vallée et al. 2019 [ ] , Melanoma (metastatic and primary) , 65 , Clone VE1 (Eurobio) , BRAF V600E , No , NS , FFPE tissue , Idylla NRAS- BRAF -EGFR S492R Mutation Test , V600 E/E2/D V600 K/R , 89 (overall) , 82,3 , 100 , 100 , 93.

Techniques: Immunohistochemistry, Mutagenesis, Immunostaining

Journal: Diagnostics

Article Title: Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

doi: 10.3390/diagnostics12030751

Figure Lengend Snippet: Comparison of Idylla and IHC for the detection of the BRAF V600E mutation in melanomas.

Article Snippet: Vallée et al. 2019 [ ] , Melanoma (metastatic and primary) , 65 , Clone VE1 (Eurobio) , BRAF V600E , No , NS , FFPE tissue , Idylla NRAS- BRAF -EGFR S492R Mutation Test , V600 E/E2/D V600 K/R , 89 (overall) , 82,3 , 100 , 100 , 93.

Techniques: Comparison, Mutagenesis, Expressing, Blocking Assay, Selection

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: Direct sequencing group—methods

Article Snippet: McKelvie (2013) , C-PCR , 71 , Spring Bioscience , NA/12 min , Unequivocal diffuse cytoplasmic staining in > 85% of tumor cells considered positive , SNaPshot used in 9 discordant cases. 8/9 VE1+/C-PCR- were confirmed positive by SNaPshot, the last case VE1+, C-PCR- and SNaPshot-.

Techniques: Sequencing, Staining, Mass Spectrometry

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: PCR group—methods

Article Snippet: McKelvie (2013) , C-PCR , 71 , Spring Bioscience , NA/12 min , Unequivocal diffuse cytoplasmic staining in > 85% of tumor cells considered positive , SNaPshot used in 9 discordant cases. 8/9 VE1+/C-PCR- were confirmed positive by SNaPshot, the last case VE1+, C-PCR- and SNaPshot-.

Techniques: Quantitative RT-PCR, Staining, Sequencing

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: Papillary thyroid carcinoma, classic type (a) showing diffuse cytoplasmic VE1 expression with moderate intensity (b); Papillary thyroid carcinoma, invasive follicular variant (c) showing negative VE1 immunostain (d). Evaluation of VE1 immunostain in papillary thyroid carcinoma at low power (e) may be deceptive. Higher power examination confirms diffuse but weak VE1 positivity (f) in a case with confirmed BRAF V600E mutation by next generation sequencing (unpublished data). These examples utilized prediluted Roche Ventana VE1 monoclonal antibody (Indianapolis, IN, USA) on the Leica Bond Refine System (Buffalo Grove, IL, USA) at 60 min incubation time

Article Snippet: McKelvie (2013) , C-PCR , 71 , Spring Bioscience , NA/12 min , Unequivocal diffuse cytoplasmic staining in > 85% of tumor cells considered positive , SNaPshot used in 9 discordant cases. 8/9 VE1+/C-PCR- were confirmed positive by SNaPshot, the last case VE1+, C-PCR- and SNaPshot-.

Techniques: Expressing, Variant Assay, Mutagenesis, Next-Generation Sequencing, Incubation

Journal: Cancers

Article Title: Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors

doi: 10.3390/cancers12071973

Figure Lengend Snippet: Anaplastic thyroid carcinoma. Common morphologic patterns include epithelial ( a ), sarcomatoid ( b ), and giant cell ( c ) pattern (H&E, 200×). Papillary carcinoma ( d ) and follicular carcinoma ( e ) coexist with the anaplastic component in an intermingled arrangement or with a sharp border (H&E, 100×). Cases positive for PAX8 ( f ), TTF-1 ( g ), and BRAF VE1 ( h ) immunostains are shown (200×).

Article Snippet: Immunohistochemical stains for PAX8 (1:400 dilution; clone 10336-1-AP; Proteintech, Rosemont, IL), TTF-1 (1:300 dilution; clone 8G7G3/1, Dako GmbH, Jena, Germany), and BRAF VE1 (1:200 dilution; clone VE1; Spring Bioscience, Pleasanton, CA, USA) were performed on Leica Bond-Max autostainer (Leica Microsystems GmbH, Wetzlar, Germany).

Techniques:

Journal: Cancers

Article Title: Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors

doi: 10.3390/cancers12071973

Figure Lengend Snippet: Summary of the results of immunohistochemistry.

Article Snippet: Immunohistochemical stains for PAX8 (1:400 dilution; clone 10336-1-AP; Proteintech, Rosemont, IL), TTF-1 (1:300 dilution; clone 8G7G3/1, Dako GmbH, Jena, Germany), and BRAF VE1 (1:200 dilution; clone VE1; Spring Bioscience, Pleasanton, CA, USA) were performed on Leica Bond-Max autostainer (Leica Microsystems GmbH, Wetzlar, Germany).

Techniques: Immunohistochemistry